Domov › Nemalobunkový karcinóm pľúc › Connecticut
Klinické štúdie Nemalobunkový karcinóm pľúc v štáte Connecticut
55 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v štáte Connecticut.
Mestá v štáte Connecticut
- New Haven41 štúdií
- East Norwalk18 štúdií
- Bridgeport14 štúdií
- Hartford12 štúdií
- Stamford8 štúdií
- Waterbury6 štúdií
- New London5 štúdií
- Norwich5 štúdií
- Norwalk3 štúdií
Oficiálny text štúdie (anglicky)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich
- a 9 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Yale University School of Medicine ( Site 0201), New Haven
- Eastern CT Hematology & Oncology Associates ( Site 0202), Norwich
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06623422Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Eastern Connecticut Hematology and Oncology Associates, Norwich
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06472245The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Yale Cancer Center, New Haven
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04585750Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #62, New Haven
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Smilow Cancer Center at Yale-New Haven ( Site 3253), New Haven
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07513376A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Yale Cancer Center, New Haven
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale - New Haven Hospital - Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- a 1 ďalších
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07090499A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- University of Connecticut Health Center ( Site 0130), Farmington
- Stamford Hospital ( Site 0126), Stamford
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Hartford HealthCare - Avon, Avon
- Hartford Hospital, Hartford
- Hartford HealthCare - Manchester, Manchester
- a 2 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06498635A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Yale Cancer Center, New Haven
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT07578571Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Yale University, Smillow Cancer Center, New Haven
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT06881784A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Stamford Hospital ( Site 0083), Stamford
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06312137A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Yale New Haven Hospital Yale Cancer Center, New Haven
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06667076A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Yale University, New Haven
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06667908Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Hartford Hospital (HH), Hartford
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06890598A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, New Have
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT07229313Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, New Haven
Prebieha náborFáza 2
Vek 18 až 95 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT05061550A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Yale New Haven Hospital /ID# 271584, New Haven
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06568939Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Yale University, Yale Cancer Center, New Haven
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 9. 2026 · NCT05983432A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, West Haven
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 9. 2026 · NCT06692738Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Yale Cancer Center, New Haven
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT07349537Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Yale University School of Medicine - Yale Cancer Center, New Haven
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT05786924Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Eastern Connecticut Hematology and Oncology Associates, Norwich
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT04613596FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Yale Cancer Center, New Haven
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT06303505A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- Yale Cancer Center, New Haven
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 9. 2026 · NCT04302025M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
- Yale Cancer Center, New Haven
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT07166601A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Hartford Hospital, Hartford
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT06793215A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Stamford Hospital ( Site 0136), Stamford
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT06345729A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Yale University School of Medicine, New Haven
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT06119581A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Yale Cancer Center, New Haven
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT05789082A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- Yale Cancer Center, New Haven
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT07361562Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- Yale Cancer Center, New Haven
- Norwalk Hospital, Norwalk
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT06343402A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Hartford Healthcare, Hartford
- Yale University, New Haven
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT07070232Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Research Site, New Haven
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 26. 8. 2026 · NCT06350097A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Yale University - Cancer Center, New Haven
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 8. 2026 · NCT06706076A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Yale University, New Haven
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 8. 2026 · NCT07111520Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Eastern Connecticut Hematology and Oncology Associates, Norwich
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 8. 2026 · NCT07397338Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Yale New Haven Hospital, Yale Cancer Center, New Haven
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 7. 2026 · NCT05098132Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich
- Smilow Cancer Hospital Care Center - Guilford, Guilford
- Smilow Cancer Hospital - Hamden Care Center, Hamden
- a 3 ďalších
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 6. 2026 · NCT04210492Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.